Kriya Therapeutics is a biopharmaceutical company focused on developing innovative gene therapies aimed at addressing significant unmet medical needs across various therapeutic areas, including neurology and ophthalmology. Their approach utilizes adeno-associated virus (AAV) gene therapy to deliver engineered ion channels that can modulate neuronal activity. For instance, Kriya is developing KRIYA-748 for trigeminal neuralgia, which aims to reduce debilitating facial pain by injecting a gene therapy that expresses a chemogenetically-gated ion channel directly into the trigeminal nerve. This channel is designed to open in the presence of varenicline, a small molecule that allows for targeted pain relief while also providing the ability to regulate the therapy's activity.

In addition to trigeminal neuralgia, Kriya is also advancing KRIYA-382 for focal epilepsy, which similarly employs a gene therapy approach to express an engineered ion channel at the site of epileptic foci in the brain. This therapy aims to minimize seizures by inhibiting neuronal hyperexcitability and is designed for one-time administration, potentially offering long-term benefits without the need for ongoing medication. Both therapies reflect Kriya's commitment to making gene therapies accessible and effective for a broader patient population, with the goal of transforming the treatment landscape for conditions that currently have limited options.

United States

Kriya Therapeutics, Inc. is a biopharmaceutical company developing gene therapies for diseases affecting millions of people around the world. With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $450 million to advance a broad pipeline of gene therapies for ophthalmology, neurology, and metabolic diseases.

Kriya Therapeutics

Company Details